
Katalognummer: 421 - 32618
Produktkategori: Företag och industri > Vetenskap och laboratorium
Storlek: 384 rxns.
32620
The ATAD2B TR-FRET Assay Kit is designed to measure the inhibition_x000D_of ATAD2B binding to its substrate in a homogeneous 384 reaction format. This FRET-based_x000D_assay requires no time-consuming washing steps, making it especially suitable for_x000D_high throughput screening applications. The assay procedure is straightforward and_x000D_simple; a sample containing terbium-labeled donor, dye-labeled acceptor, ATAD2B,_x000D_substrate, and an inhibitor is incubated for sixty minutes. Then, the fluorescence_x000D_intensity is measured using a fluorescence reader.
32601
The ATAD2A Inhibitor Screening Assay Kit is designed to measure the inhibition of ATAD2A binding to its substrate. The key to the ATAD2A Inhibitor Screening Assay Kit is a specific binding of the ATAD2A bromodomain to the acetylated histone substrate. With this kit, only three simple steps on a microtiter plate are required. First, a sample containing ATAD2A and an inhibitor of choice is incubated with the biotinylated substrate for thirty minutes. Next, acceptor beads are added, then donor beads, followed by reading the Alpha-counts.
31109
Human Bromodomain ATAD2A, also known as ANCCA and ATPase Family AAA Domain-containing Protein 2, GenBank Accession No. NM_014109, a.a. 981 - 1108 corresponding to single bromodomain with N-terminal His-tag, MW = 16.2 kDa, expressed in an E. coli expression system.
52078
The EZH2 (Y641N) TR-FRET Assay Kit is designed to measure activity of the_x000D_mutant EZH2 complex [EZH2 (Y641N)/EED/SUZ12/RbAp48/AEBP] in a homogeneous 384_x000D_reaction format. This FRET-based assay requires no time-consuming washing steps, making it_x000D_especially suitable for high throughput screening applications. The key to the EZH2 (Y641N) Assay Kit is a_x000D_highly specific antibody that recognizes methylated Histone H3K27. With this kit, only three_x000D_simple steps on a microtiter plate are required for methyltransferase detection. First, Sadenosylmethionine_x000D_is incubated with a sample containing assay buffer and methyltransferase_x000D_enzyme for 4 hours. Next, antibody to methylated H3K27 is added. Finally, dye-labeled acceptor_x000D_is added followed by fluorescence detection.
52680
The EZH2 (Y641F) TR-FRET Assay Kit is designed to measure activity of the mutant EZH2 complex (EZH2 (Y641F)/EED/SUZ12/RbAp48/ AEBP) in a homogeneous 384 reaction format. This FRET-based assay requires no timeconsuming washing steps, making it especially suitable for high throughput screening applications. The EZH2 (Y641F) TR-FRET Assay Kit comes in a convenient format, with histone H3 peptide substrate, a Tb-labeled antibody against methylated K27 residue of Histone H3, S-adenosylmethionine, methyltransferase assay buffer, TR-FRET detection buffer, dye-labeled acceptor, and purified EZH2 (Y641F) complex for 384 enzyme reactions. The key to the EZH2 (Y641F) Assay Kit is a highly specific antibody that recognizes methylated Histone H3K27. With this kit, only three simple steps on a microtiter plate are required for methyltransferase detection. First, S-adenosylmethionine is incubated with a sample containing assay buffer and methyltransferase enzyme for 240 minutes. Next, antibody is added. Finally, dye-labeled acceptor is added followed by fluorescence reading.
79575
Human Casitas B-lineage lymphoma proto-oncogene b (CBL-B) is an E3 ubiquitinprotein ligase that functions as a negative regulator of T-cell activation. It is a promising drug target in cancer immunotherapy. The CBL-B TR-FRET Assay Kit is designed to measure CBL-B auto-ubiquitination activity in a homogeneous 384 reaction format. It utilizes biotin-labeled Ubiquitin and a terbium-labeled anti-CBL-B antibody to complete the TR-FRET pairing. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications.

By: Author , 2 Comment
23 August 2025

By: Author , 2 Comment
16 August 2025

By: Author , 2 Comment
1 August 2025

By: Author , 2 Comment
22 July 2025

